ClinicalTrials.gg
Not yet recruitingNCT07774624Updated Aug 19, 2026

Study of SKB103 in HER2-negative Breast Cancer

A Phase 1/2 interventional study of SKB103 monotherapy in Breast Cancer, sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (part of Sichuan Kelun Pharmaceutical Co.,Ltd.) · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
140
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a Phase I/II clinical study to evaluate the safety and efficacy of SKB103 in participants with advanced (locally advanced, recurrent, or metastatic) HER2-negative breast cancer. The study includes a Phase 1 dose escalation stage and a Phase 2 indication expansion stage.

Read the detailed description

This is a multi-center, open-label, phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and efficacy of SKB103 in participants with locally advanced, recurrent or metastatic HER2-negative breast cancer.

The study includes a Phase 1 dose escalation stage and a Phase 2 indication expansion stage.

02

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • HER2-negative Breast Cancer
  • Breast Cancer
  • SKB103
03

In context

Breast Neoplasms

14,848 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

This study's planned enrollment of 140 is above the median of 72 across 10,914 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is the lead sponsor of 55 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Willingness to participate in the study, sign the form(ICF), and comply with the protocol-specified visits and relevant procedures.
  2. Aged ≥ 18 and ≤ 75 years at the time of signing ICF.
  3. and/or cytologically confirmed -negative Breast cancer who have failed standard therapy.
  4. Participants should provide tumor tissue samples for biomarker testing as much as possible.
  5. At least one per v1.1.
  6. (ECOG) score is 0 or 1.
  7. ≥ 12 weeks.
  8. Acceptable bone marrow and organ function.
  9. Male and female participants must agree to use highly effective methods during the study period.

Key Exclusion Criteria:

  1. Participants with known meningeal , brainstem metastases, spinal cord metastases and/or compression, and active central nervous system (CNS) metastases.
  2. Participants with other malignant tumors within 3 years prior to the first administration.
  3. Presence of any serious cardiovascular and cerebrovascular diseases or cardiovascular and cerebrovascular risk factors.
  4. Presence of any uncontrolled systemic disease, as judged by the investigator.
  5. Presence of pleural effusion, pericardial effusion, or ascites with clinical symptoms or requiring repeated drainage.
  6. History of interstitial lung disease or noninfectious pneumonitis.
  7. Other lung diseases that may interfere with drug-related pulmonary toxicity or may cause clinically serious lung injuries.
  8. Documented severe dry eye syndrome, severe meibomian gland disease and/or blepharitis, or history of corneal disorders that prevent/delay corneal healing.
  9. Presence of risk of developing esophagotracheal fistula or esophageal pleural fistula, or tumor invasion or compression of surrounding vital organs and major blood vessels with related clinical symptoms.
  10. Clinical symptoms of intestinal obstruction, gastrointestinal perforation or fistula, urethral fistula, and abdominal abscess within 3 months prior to the first administration.
  11. Toxicities from prior anti-tumor therapy not recovering to ≤ Grade 1.
  12. Has experienced immune-related adverse events (irAE) of Grade 3 or higher during prior immunotherapy
  13. Serious infection occurred within 4 weeks prior to the first administration.
  14. Active or .
  15. Positive result of (HIV) test or history of acquired immunodeficiency syndrome (AIDS); Known active syphilis infection.
  16. Known active pulmonary tuberculosis.
  17. Known history of allogeneic organ transplantation or hematopoietic stem cell transplantation.
  18. History of allergies to any component of SKB103 injection, or severe reaction to other monoclonal antibodies.
  19. Has received prior antibody or drug therapy targeting T-cell co-stimulatory or checkpoint pathways, or cell therapy.
  20. Received chemotherapy, immunotherapy, biological therapy, or other large molecule anti-tumor drugs within 4 weeks prior to the first administration.
  21. Has received radiation therapy to lung lesions with a total dose >30 Gy within 6 months prior to the first dose of study drug.
  22. Participants who received major surgeries 4 weeks prior to the first administration.
  23. Participants who received other drugs within 4 weeks prior to their first administration.
  24. Participants who have previously received anti-tumor vaccines or have received any within 4 weeks prior to the first administration or scheduled to receive live vaccines during study treatment.
  25. Receipt of systemic therapy (>10mg of prednisone or its equivalent) or other agents within 2 weeks prior to the first dose.
  26. Receipt of strong inhibitors or inducer of cytochrome P450() or inhibitors of breast cancer resistance protein (BCRP) within 2 weeks prior to the first administration or within 5 half-lives of the known drugs(whichever is longer).
  27. Pregnant or lactating women.
  28. Known history of psychiatric disorder or substance abuse that may interfere with study compliance.
  29. Has any local or systemic condition (non malignant or tumor related) that may impair protocol compliance.
  30. Any condition that, in the opinion of the Investigator, may interfere with the evaluation of the study drug, participant safety, or interpretation of the study results; or any other condition that the investigator deems unsuitable for participation in this study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Participant Group

    Drug: SKB103 monotherapy

Interventions

  • DrugSKB103 monotherapy

    SKB103 for injection, administered as monotherapy via intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks, Q3W). Treatment continues until radiographic disease progression (PD), intolerable toxicity, participant request for discontinuation, lost to follow-up, or death, whichever occurs first.

06

What researchers measure

Primary outcomes

  1. Number of subjects achieving Dose-limiting toxicity (DLT)

    DLT is defined as any adverse event (AE) that meets protocol-defined DLT criteria, occurring in the first 21 days, and considered at least possibly drug-related.

    Time frame: Within the first 21 days following the initial dose.

  2. Objective response rate(ORR)

    ORR is defined as the proportion of participants with confirmed complete response (CR) or partial response (PR) as the best overall response assessed per RECIST 1.1.

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. Progression-free survival (PFS)

    PFS is defined as the time from the first dose to progressive disease (PD) or death, whichever occurs first. PD will be assessed per RECIST 1.1.

    Time frame: Up to approximately 3 years

  2. Duration of Response (DOR)

    Time from the start of the first assessment of CR or PR in participants to PD or death due to any reason.

    Time frame: Up to approximately 3 years

  3. Disease control rate (DCR)

    DCR is defined as the proportion of participants with CR, PR or stable disease (SD) as the best overall response assessed per RECIST 1.1.

    Time frame: Up to approximately 3 years

  4. Overall Survival (OS)

    Time from start of treatment to death due toany reason.

    Time frame: Up to approximately 3 years

  5. Cmax

    Maximum Plasma Concentration (Cmax) of SKB103-ADC, SKB103-TAB, and free KL610348.

    Time frame: Up to approximately 3 years

  6. Cmin

    Minimum Observed Plasma Concentration (Cmin) of SKB103-ADC, SKB103-TAB, and free KL610348.

    Time frame: Up to approximately 3 years

  7. Immunogenicity

    Presence of Anti-drug antibodys (ADAs) for SKB103

    Time frame: Up to approximately 3 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Dec 2029, 40 months later.

Of 164 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 40 months is below that.

Counting every sponsor, half of 331 studies reached it within 62 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2026
First posted
Aug 19, 2026
StartEst.
Aug 31, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2030
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07774624
Responsible party
Sponsor
First posted
Aug 19, 2026
Start date
Aug 31, 2026 (estimated)
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Aug 19, 2026

Study contacts

Yina Diao
Contact
diaoyina@kelun.com
86-028-67252634

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion